# Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive

> **Open Intelligence Dossier** · First detected: 2026-07-20 21:07 UTC · Category: Business

## Executive Summary
Tempus AI is acquiring cancer-monitoring firm Personalis in a deal valued at approximately $1.5 billion, though market reaction has been negative.

## Intelligence Brief
Tempus AI has entered into an agreement to acquire Personalis, a company specializing in cancer monitoring and genomics. According to reports from Reuters, qz.com, and Fierce Biotech, the transaction is primarily a stock deal. While most sources, including Investor's Business Daily and Fierce Biotech, value the acquisition at $1.5 billion, Bloomberg.com reports the figure as $1.7 billion. The move is designed to integrate Personalis's capabilities into the existing AI-enabled precision oncology platform managed by Tempus AI. Coverage from Business Wire emphasizes that the acquisition is intended to more tightly integrate Molecular Residual Disease, commonly referred to as MRD, into the Tempus AI ecosystem.


This specific technical focus is a central theme across the reporting. Several outlets, including Barron's and Investor's Business Daily, highlighted the immediate financial fallout of the announcement. Specifically, these reports note that the shares of both Tempus AI and Personalis experienced a dive or sink following the news of the deal. To understand the context of this acquisition, it is necessary to note that Personalis had previously functioned as a cancer genomics partner to Tempus AI. The transition from a partnership to a full buyout indicates a strategic shift toward ownership of cancer test manufacturing and monitoring technologies.


The integration of MRD into a precision oncology platform suggests a move toward more comprehensive cancer monitoring tools, though the disparity in reported deal values between Bloomberg and other outlets remains a point of note. Observers will likely monitor the actual finalization of the stock deal and the subsequent performance of the shares for both companies. Because the stocks for both Tempus AI and Personalis sank upon the announcement, market analysts will be watching for signs of recovery or further volatility. Future developments will likely center on how the Molecular Residual Disease integration is implemented within the AI-enabled platform as described in the Business Wire announcement.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| qz.com | Tempus AI is acquiring cancer-monitoring firm Personalis in a $1.5 billion stock deal | [Source Link](https://news.google.com/rss/articles/CBMiiAFBVV95cUxNSXlaUGlrWWxFc2hLZzJ3amJZQ0ZZczZ1Qmk5X0JMcXRKREZpcERGa3dzc1JXRlJFN19lN3ZCS25qN1ZhbERjdm5WUEJ4bXRXSGRhSF9NRU03cGdfaVp6dmszS2hFYklZalBNMmxReHZPQlF0c2dKTU9UY2g0cnNtNkh1blEzVEM0?oc=5) |
| Bloomberg.com | Tempus AI to Buy Cancer-Tech Firm Personalis For $1.7 Billion | [Source Link](https://news.google.com/rss/articles/CBMisAFBVV95cUxOMEllS2RoRDEwcjk1aGFER0U4QWE5am9zRXpYTmxxUS1oX0xhcDF6OGtyUl92SHhvTlU2VE9OYnJyQUxCM3dGNDhMNkFCSTNRS045S1pqdWVsLWc0clFNVWhwbU1LdGc2NGo3NnZ3NVNKY25sV0c3NzhwMks1aVlDRzhrb01UYS1zQjhNTVR3b0NGMGJvanpiNFVfU3l3T2diR0h5VS1feVpqcnlDa3Q2Ug?oc=5) |
| Fierce Biotech | Tempus buys out cancer genomics partner Personalis in $1.5 billion deal | [Source Link](https://news.google.com/rss/articles/CBMiqwFBVV95cUxOa1FoT3N1SG1xRzRtQzduM0FrREVlZUlIZGN5S0ktWEtYUl9ZbDJMbTVzOGxtZm14QzJvWjlTM2tPSTFibWtobUVfT1NIUnVoMDl0ODZiMThvM285WVE5TElZRVEyTDJqdFBIc0JPXzg0MjdhRUhyNVRIS3RnQUoxYkxBWnlHWUhmRWZXREd0UDhENkhQN2J6RG1PaFhiV3ZGVDBWVlY5V0lmbGs?oc=5) |
| Business Wire | Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform | [Source Link](https://news.google.com/rss/articles/CBMimAJBVV95cUxOX2tRZmFKM1NJSjRqM2MzYXVsd2h2bHlQZzRoOWJZTy1HbVZzaGJpWVluMk1PWDk3OXpCRUNHdUVpeGdqTW5MRVhnNXJjZ3lCNEFtT3JtMHpKVUk5SzRtTldwQjZ6WURNbGpINDJuSUdFd3ZhT2RJVGExNzcyQWtpd2ltcVo2LUF2dXZ6d3BOMXNYdkpXY0ZDMW1jUEtpRjExWVpHVTNwZ2VXMFRxaVVRY21PamhRcW5yR0tKbGZkZjZndDI2VmJiMUp1eFdweTJvWXVvRDk2aUhVU01JbEotaVRHLU9HVW11OUFONmF0QjlIZFFLZzFzSmZpWjFKOVFmUThiMVpRTlYzRk85NlByeFgzcldhTHZT?oc=5) |
| Barron's | Tempus AI Buys Personalis for $1.5 Billion, and Both Stocks Sink | [Source Link](https://news.google.com/rss/articles/CBMihwFBVV95cUxPRllUSld5WC04cnpZRWhkWW5zbzVGUzJTMlcydm1yM0x4OXpqVWFKU1hUaXVLd2d3OURfaVBnSmc3WVNzU09hU0IyQlBPQ05QWWdWXzFYZU9NaXI4THVTYWRtR05VOXNESDZ2T01EdENuUGN4SWh5Y3NLSFZ2eUd4OTFFb3JOR1E?oc=5) |
| Reuters | Tempus to buy cancer test maker Personalis for $1.5 billion | [Source Link](https://news.google.com/rss/articles/CBMirAFBVV95cUxOeDdaUjUzN3pPOUFOZFZnRDQtelVrYUFKcDFGZUxMXzhxVFlQejhnSWJ2b2VkM2h0YnRfRXJ6Qm0tMFQ5eWNLZW4yRncwZXVvN2dZWFE4LS02WkRuS2JiblQ0U3VVSm9jaGs5TjdtNnhzLXFBMUNuYXlUd2o0OGxwd0kzaVc3UUZ5QUJBQmpfVFNOSkN3c0RKcktoekRBMFJENEFBa0JranFHSjJs?oc=5) |
| Investor's Business Daily | Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive | [Source Link](https://news.google.com/rss/articles/CBMifEFVX3lxTE9OTzZlWV9BUzQwTU5yNzlUZkRzbVZqcXRaTURmd1RRRVZaRTNTUHdNWnZKRW1LOGg0bERpRnF0RWpuNno2WmtmNHNqNHhXZHkxM1pLN1QtQVAzUV8tUmE0Z1ctLU45bmVJNy1zSXR1aUJMaGxFUHNqNGRtR0k?oc=5) |

---
*Canonical Source: https://pulse.byoviral.com/trend/2026-07-20/tempus-ai-scoops-up-personalis-for-1-5-billion-but-shares-dive*